Happy anniversary for human cytomegalovirus

Reviews in Medical Virology

Volumn 16, Issue 6, 2006, Pages 349-352

  Griffiths, Paul D ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; VALACICLOVIR;

CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG ACTIVITY; EDITORIAL; ERADICATION THERAPY; FIBROBLAST CULTURE; HUMAN; HUMAN CYTOMEGALOVIRUS; NONHUMAN; OPEN READING FRAME; PHENOTYPE; VACCINE PRODUCTION; VIRUS IMMUNITY; VIRUS ISOLATION; VIRUS STRAIN;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; HISTORY, 20TH CENTURY; HUMANS; VIROLOGY;

EID: 33751092520     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.523     Document Type: Editorial

References (33)

1. Smith MG. Propagation in tissue cultures of a cytopathogenic virus from human salivary gland virus (SGV) disease. Proc Soc Exp Biol Med 1956; 92(2): 424-430.
2. Rowe WP, Hartley JW, Waterman S, Turner HC, Huebner RJ. Cytopathogenic agent resembling human salivary gland virus recovered from tissue cultures of human adenoids. Proc Soc Exp Biol Med 1956; 92(2): 418-24.
3. Weller TH, Macauley JC, Craig JM, Wirth P. Isolation of intranuclear inclusion producing agents from infants with illnesses resembling cytomegalic inclusion disease. Proc Soc Exp Biol Med 1957; 94(1): 4-12.
4. McGeoch DJ, Cook S, Dolan A, Jamieson FE, Telford EA. Molecular phylogeny and evolutionary time-scale for the family of mammalian herpesviruses. J Mol Biol 1995; 247(3): 443-458.
5. Chee MS, Bankier AT, Beck S, et al. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol 1990; 154: 125-169.
6. Dolan A, Cunningham C, Hector RD, et al. Genetic content of wild-type human cytomegalovirus. J Gen Virol 2004; 85(Pt 5): 1301-1312.
7. Singh N. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Rev Med Virol 2006; 16(5): 281-287.
8. Snydman DR. The case for cytomegalovirus prophylaxis in solid organ transplantation. Rev Med Virol 2006; 16(5): 289-295.
9. Emery VC, Cope AV, Bowen EF, Gor D, Griffiths PD. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 1999; 190(2): 177-182.
10. Emery VC, Hassan-Walker AF, Burroughs AK, Griffiths PD. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. J Infect Dis 2002; 185(12): 1723-1728.
11. Mar EC, Chiou JF, Cheng YC, Huang ES. Human cytomegalovirus-induced DNA polymerase and its interaction with the triphosphates of 1-(2′-deoxy- 2′-fluoro-beta-D-arabinofuranosyl)-5-methyluracil, -5-iodocytosine, and -5-methylcytosine. J Virol 1985; 56(3): 846-851.
12. Talarico CL, Burnette TC, Miller WH, et al. Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Antimicrob Agents Chemother 1999; 43(8): 1941-1946.
13. Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992; 358(6382): 160-162.
14. Balfour HH Jr., Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320(21): 1381-1387.
15. Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994; 343(8900): 749-753.
16. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340(19): 1462-1470.
17. Cha TA, Tom E, Kemble GW, Duke GM, Mocarski ES, Spaete RR. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol 1996; 70(1): 78-83.
18. Weller TH. Pathogenesis of human cytomegalovirus-associated diseases. Historical perspective. Transplant Proc 1991; 23(3 Suppl 3): 5-6, discussion.
19. Mocarski ES Jr. Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol 2002; 10(7): 332-339.
20. Pignatelli S, Dal Monte P, Rossini G, Landini MP. Genetic polymorphisms among human cytomegalovirus (HCMV) wild-type strains. Rev Med Virol 2004; 14(6): 383-410.
21. Klenerman P, Hill A. T cells and viral persistence: lessons from diverse infections. Nat Immunol 2005; 6(9): 873-879.
22. Moss P, Khan N. CD8(+) T-cell immunity to cytomegalovirus. Hum Immunol 2004; 65(5): 456-464.
23. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202(5): 673-685.
24. Olsson J, Wikby A, Johansson B, Lofgren S, Nilsson BO, Ferguson FG. Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. Mech Ageing Dev 2000; 121(1-3): 187-201.
25. Ouyang Q, Wagner WM, Wikby A, et al. Large numbers of dysfunctional CD8+ T lymphocytes bearing receptors for a single dominant CMV epitope in the very old. J Clin Immunol 2003; 23(4): 247-257.
26. Wikby A, Maxson P, Olsson J, Johansson B, Ferguson FG. Changes in CD8 and CD4 lymphocyte subsets, T cell proliferation responses and non-survival in the very old: the Swedish longitudinal OCTO-immune study. Mech Ageing Dev 1998; 102(2-3): 187-198.
27. Almanzar G, Schwaiger S, Jenewein B, et al. Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J Virol 2005; 79(6): 3675-3683.
28. Khan N, Shariff N, Cobbold M, et al. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 2002; 169(4): 1984-1992.
29. Trzonkowski P, Mysliwska J, Szmit E, et al. Association between cytomegalovirus infection, enhanced proinflammatory response and low level of antihemagglutinins during the anti-influenza vaccination - an impact of immunosenescence. Vaccine 2003; 21(25-26): 3826-3836.
30. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340(2): 115-126.
31. Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 2003; 289(8): 1008-1011.
32. Griffiths PD, McLean A, Emery VC. Encouraging prospects for immunisation against primary cytomegalovirus infection. Vaccine 2001; 19(11-12): 1356-62.
33. Stratton KR, Durch JS, Lawrence RS. Vaccines for the 21st Century. National Academy Press: Washington, DC; 2000.